Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jacr.2010.03.023 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of UV-A and UV-B transmission through the windows of gas, hybrid, and electric vehicles.
Arch Dermatol Res
January 2025
Department of Dermatology, Drexel University College of Medicine, 860 1St Avenue, Suite 8B, Philadelphia, PA, 19406, USA.
UV-A exposure is a major risk factor for melanoma, nonmelanoma skin cancer, photoaging, and exacerbation of photodermatoses. Since people spend considerable time in cars daily, inadequate UV-A attenuation by car windows can significantly contribute to the onset or exacerbation of these skin diseases. Given recent market trends in the automobile industry and known impact of car windows on cumulative lifelong UV damage to the skin, there is a need to comparatively evaluate UV transmission across windows in electric vehicles (EV), hybrid vehicles (HV), and gas vehicles (GV) as well as variability based on year of manufacture and mileage to inform car manufacturers and consumers of the potential for UV exposure to the skin based on vehicle.
View Article and Find Full Text PDFEfficacy and safety of Anlotinib in combination with gemcitabine and cisplatin as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A single-arm clinical trial.
Int J Cancer
January 2025
Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China.
The effectiveness and safety of combining anlotinib with gemcitabine and cisplatin in the first-line treatment of recurrent/metastatic nasopharyngeal carcinoma (R/M NPC) have not been definitively established. This research seeks to investigate the potential benefits and risks of utilizing this combination therapy in the first-line management of R/M NPC. The research involved 22 individuals diagnosed with R/M NPC and who had not undergone any previous treatment.
View Article and Find Full Text PDFEstimating Human Fat and Muscle Conductivity From 100 Hz to 1 MHz Using Measurements and Modelling.
Bioelectromagnetics
January 2025
Seibersdorf Labor GmbH, Seibersdorf, Austria.
The electrical conductivity of human tissues is a major source of uncertainty when modelling the interactions between electromagnetic fields and the human body. The aim of this study is to estimate human tissue conductivities in vivo over the low-frequency range, from 30 Hz to 1 MHz. Noninvasive impedance measurements, medical imaging, and 3D surface scanning were performed on the forearms of ten volunteer test subjects.
View Article and Find Full Text PDFRole of stereotactic radiosurgery for intracranial epidermoid tumors: a systematic review to assess its safety, efficacy, and complication profile.
J Neurooncol
January 2025
University of Virginia, Charlottesville, VA, USA.
Background: Even a gross total resection of a benign epidermoid tumor (ET) carries a high risk of recurrence. The management strategy mostly involves redo surgical excision but at a significant cost of morbidity and mortality. The role of adjuvant radiation therapies in this scenario is still undefined.
View Article and Find Full Text PDFSurvey and perspective on verification, validation, and uncertainty quantification of digital twins for precision medicine.
NPJ Digit Med
January 2025
Laboratory for Information and Decision Systems, Massachusetts Institute of Technology, Cambridge, MA, USA.
Digital twins in precision medicine provide tailored health recommendations by simulating patient-specific trajectories and interventions. We examine the critical role of Verification, Validation, and Uncertainty Quantification (VVUQ) for digital twins in ensuring safety and efficacy, with examples in cardiology and oncology. We highlight challenges and opportunities for developing personalized trial methodologies, validation metrics, and standardizing VVUQ processes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!